ABVC BioPharma
ABVC
13 hedge funds and large institutions have $241K invested in ABVC BioPharma in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 0 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
55% more capital invested
Capital invested by funds: $156K → $241K (+$85.2K)
44% more funds holding
Funds holding: 9 → 13 (+4)
1.32% more ownership
Funds ownership: 1.84% → 3.15% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$58.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.7K |
| 3 |
VF
Virtu Financial
New York
|
+$8.89K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$6.14K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$33 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APP
1
Avantax Planning Partners
Dubuque,
Iowa
| $84.9K | +$58.6K | +104,968 | +269% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $46.8K | +$4.28K | +7,678 | +11% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $27.7K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $24K | +$22.7K | +40,743 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $20.3K | +$6.14K | +11,000 | +47% |
|
6
Northern Trust
Chicago,
Illinois
| $11.3K | – | – | – |
|
|
VF
7
Virtu Financial
New York
| $9K | +$8.89K | +15,935 | New |
|
8
State Street
Boston,
Massachusetts
| $7.61K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| $7.43K | +$109 | +196 | +2% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1.51K | -$33 | -60 | -2% |
|
|
SS
11
SBI Securities
Tokyo,
Japan
| $391 | +$369 | +662 | New |
|
12
Bank of America
Charlotte,
North Carolina
| $48 | +$2 | +3 | +4% |
|
13
UBS Group
Zurich,
Switzerland
| $6 | +$6 | +10 | New |
|
ABVC Hedge Fund Activity: Q4 2024 in Review
13 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2024, worth a combined $241K — up 55% from $156K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ABVC positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Avantax Planning Partners, adding an estimated $58.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $33.
- 13 institutional investors held ABVC BioPharma (ABVC) as of Q4 2024, up from 9 in Q3 2024.
- Funds reported $241K of ABVC BioPharma stock for Q4 2024, up 55% quarter-over-quarter.
- 4 funds opened new ABVC BioPharma positions in Q4 2024 and 0 closed out, a net change of +4 holders.
- The largest ABVC BioPharma buyer in Q4 2024 was Avantax Planning Partners, an estimated $58.6K added.
- The largest ABVC BioPharma seller in Q4 2024 was Tower Research Capital (TRC), an estimated $33 sold.
Based on aggregated 13F filings for Q4 2024.